

Rep. Kesselring, Hills. 18  
Rep. Kofalt, Hills. 32  
Rep. Mazur, Hills. 44  
Rep. Cole, Hills. 26  
Rep. Miles, Hills. 12  
February 11, 2026  
2026-0666h  
05/07

Amendment to HB 1734-FN

1 Amend RSA 126-ZZ:3 as inserted by section 2 of the bill by inserting after paragraph IV the  
2 following new paragraph:

3

4 V. Nothing in this chapter shall prohibit an experimental treatment center from conducting  
5 clinical research protocols. Clinical research protocols may be approved by an institutional review  
6 board (IRB) meeting pursuant to 45 C.F.R. Part 46 or by a scientific review board established under  
7 this chapter. Research protocols may employ any study design, participant stratification, outcome  
8 measurement, or monitoring approach consistent with the protocol's scientific and ethical  
9 justification. Clinical research conducted under this section shall maintain all study records,  
10 including protocols, consent forms, case reports, and safety data, for not less than 3 years and shall  
11 make such records available to state or federal regulatory authorities upon reasonable request or  
12 where disclosure is required by law or regulation. Sites conducting research under this chapter  
13 consent to inspection by state or federal regulatory authorities, at reasonable times and upon  
14 reasonable request, as necessary to verify compliance with applicable requirements.

15

16 Amend RSA 126-ZZ:5, IV as inserted by section 2 of the bill by replacing it with the following:

17

18 IV. Authorized providers may administer experimental treatments to eligible patients  
19 pursuant to RSA 126-ZZ:2, II if reviewed and approved by a scientific review board established  
20 under this chapter. The scientific review board shall determine the appropriate quality standards,  
21 documentation requirements, and clinical oversight for each treatment protocol, which may include  
22 quality frameworks and documentation standards recognized by international regulatory  
23 authorities. The scientific review board shall include not fewer than 3 members with appropriate  
24 expertise and shall include at least one licensed physician and at least one member with experience  
25 in clinical outcomes research. Providers may share scientific review boards or board members with  
26 other authorized facilities or with academic institutions.

27

28 Amend RSA 126-ZZ:6, I as inserted by section 2 of the bill by replacing it with the following:

29

**Amendment to HB 1734-FN**  
**- Page 2 -**

1           I. Authorized experimental treatment centers may manufacture drugs, biologics, or devices  
2 on-site or through contracted facilities, provided the center's scientific review board approves the  
3 manufacturing protocol and determines it meets quality standards equivalent to recognized  
4 pharmaceutical manufacturing frameworks for patient safety. The scientific review board shall  
5 determine the appropriate quality framework for manufacturing and compounding under this  
6 chapter for purposes of clinical use in experimental treatment centers.

7

8 Amend RSA 126-ZZ:6 as inserted by section 2 of the bill by inserting after paragraph IV the  
9 following new paragraph:

10

11           V. Nothing in this section shall be construed to alter the jurisdiction or authority of the  
12 board of pharmacy under RSA 318.